Notably, since the venous EC population (containing rESCs) expanded upon anti-VEGF treatment of tumor-bearing mice, these findings raise the question whether an enlarged pool of rESCs may contribute to the resistance against anti-VEGF therapy. The gene discussed is VEGFA; the disease is neoplasm.